pakistan
Russian company to establish insulin manufacturing plant in Pakistan
Key takeaways
- Under the plan, the two companies will establish an aseptic filling plant and an insulin manufacturing facility in Pakistan in two phases.
- The first phase is expected to be completed by December 2028, while the second phase is scheduled for completion by December 2031.
- The development comes as DRAP allowed the Russian manufacturer and its local partner to market Rosinsulin R, Rosinsulin C, and Rosinsulin M 30/70 insulin products.
Why this matters: local context for readers following news across Pakistan and the region.
Add ARY News on Google AAResize KARACHI: Russian firm Zavod Medsintez and its local partner, Genetics Pharmaceuticals Private Limited, plan to invest around $80 million in Pakistan’s pharmaceutical sector to begin local production of insulin, sources said on Monday.
Under the plan, the two companies will establish an aseptic filling plant and an insulin manufacturing facility in Pakistan in two phases.
The first phase is expected to be completed by December 2028, while the second phase is scheduled for completion by December 2031.
Article preview — originally published by ARY News. Full story at the source.
Read full story on ARY News →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from ARY News alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop